Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encelle plans hydrogel matrix wound-healing trial:

This article was originally published in Clinica

Executive Summary

Encelle has received a $100,000 grant from the US National Institutes of Health to evaluate its hydrogel matrix in wound-healing applications. The Raleigh, North Carolina company recently filed an investigational device exemption with the FDA and hopes to begin clinical trials of the product later this year. The matrix, an injectable biopolymer material, promotes the growth of new blood vessels and wound closing by mimicking processes in the body that occur during embryonic development. Encelle added that because the product may enable relatively scar-free healing, it could also be used in general and plastic surgery.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel